RC
ABEO icon

Rangeley Capital’s Abeona Therapeutics ABEO Stock Holding History

Rangeley Capital’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$269K Buy
60,000
+2,400
+4% +$12K 0.26% 81
2025
Q4 		$304K Buy
+57,600
New +$290K 0.25% 71

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rangeley Capital's ABEO Position: Q1 2026 in Review

Rangeley Capital increased its Abeona Therapeutics (ABEO) stake by 4.2% in Q1 2026, buying an estimated $12K and bringing the position to 60,000 shares worth $269K. The position accounts for 0.26% of the portfolio, ranked #81.

Rangeley Capital first reported a position in ABEO in Q4 2025 and has held it in 2 quarters since. The position peaked at $304K in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Rangeley Capital held 60,000 shares of Abeona Therapeutics worth $269K as of Q1 2026.
  • Rangeley Capital bought 2,400 Abeona Therapeutics shares in Q1 2026, an estimated $12K.
  • Abeona Therapeutics made up 0.26% of Rangeley Capital's portfolio in Q1 2026, its #81 holding.
  • Rangeley Capital first reported a position in Abeona Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Rangeley Capital's Abeona Therapeutics position peaked at $304K in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.